Stockreport

Why IDEAYA Biosciences (IDYA) Is Down 5.2% After Completing Enrollment In Pivotal Uveal Melanoma Trial [Yahoo! Finance]

IDEAYA Biosciences, Inc.  (IDYA) 
Last ideaya biosciences, inc. earnings: 3/24 06:00 am Check Earnings Report
PDF inhibitor darovasertib plus Pfizer's crizotinib in first-line HLA*A2-negative metastatic uveal melanoma, while also advancing IDE034 and IDE574 into early-stage clinical [Read more]